Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private PlacementGlobeNewsWire • 06/27/24
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross ProceedsGlobeNewsWire • 06/24/24
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/14/24
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/13/24
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)GlobeNewsWire • 05/21/24
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/24
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingGlobeNewsWire • 04/23/24
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)GlobeNewsWire • 03/06/24
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateGlobeNewsWire • 02/13/24
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerGlobeNewsWire • 01/24/24
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital HyperinsulinismGlobeNewsWire • 01/23/24
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital HyperinsulinismGlobeNewsWire • 12/14/23
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)GlobeNewsWire • 12/13/23
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"Newsfile Corp • 11/24/23
Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric StudySeeking Alpha • 11/09/23
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital HyperinsulinismGlobeNewsWire • 10/17/23
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated HyperinsulinismGlobeNewsWire • 10/11/23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company ProgressGlobeNewsWire • 09/14/23
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital HyperinsulinismGlobeNewsWire • 06/27/23
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseNewsfile Corp • 06/01/23